What insurance policy changes affect code K59.09?

There are 11 tracked policy changes affecting code K59.09, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code K59.09?

Payers that have issued tracked updates for code K59.09 include: Aetna.

How do I get notified when code K59.09 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code K59.09. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code K59.09?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

K59.09 Insurance Policy Changes

ICD-10 K59.09 is officially defined as "Other constipation." code K59.09 is referenced in 11 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code K59.09 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 29, 2026Medium impact
Transanal Endoscopic Microsurgery (CPB 0747, reviewed 2026-10-21)
Aetna's Clinical Policy Bulletin 0747, last reviewed 10/21/2026, covers transanal endoscopic microsurgery (TEM). Aetna considers TEM medically necessary for benign rectal tumors (adenomas), low-risk Tis and T1 rectal carcinoma, and small rectal carcinoids less than 2 cm in diameter. Aetna considers TEM experimental, investigational, or unproven for other indications, including advanced rectal cancer, anorectal melanoma, benign rectal strictures, rectal prolapse and diverticula, and megacolon. The source text does not describe what changed in this review.
Aetna · Identified Oct 5, 2026Medium impact
Lead Testing (CPB 0553, reviewed 2026-08-28)
Aetna considers blood lead testing medically necessary for diagnosis of persons with signs and symptoms of lead poisoning and for pregnant or lactating women who have any listed lead exposure risk factor. Lead screening is covered for persons with occupational lead exposure and, as a preventive service, for children in listed high-risk groups. Measurement of lead in bone, hair, teeth, or urine is considered experimental, investigational, or unproven.
Aetna · Identified Oct 1, 2026Medium impact
Bowel Management Devices (CPB 0522, reviewed 2026-08-18)
Aetna's Clinical Policy Bulletin 0522 covers bowel management devices. It considers manual pump enema systems medically necessary for chronic neurogenic bowel after diet, bowel habit, laxatives or constipating medications have failed, gravity-administered enema systems for constipation, fecal incontinence and bowel management protocols, and a stent for bowel obstruction due to colorectal malignancy for palliation and as a bridge to surgery. It considers manual pump enema systems for idiopathic constipation and fecal incontinence, the Navina Smart System, ingestible vibrating capsule devices, pulsed irrigation evacuation systems and rectal inserts experimental, investigational or unproven.
Aetna · Identified Aug 19, 2026Medium impact
Inflammatory Disease: Biomarker and Thiopurine Pharmacogenomic Testing (CPB 0249, reviewed 2026-04-27)
In inflammatory bowel disease (IBD) and rheumatoid arthritis, TPMT gene or phenotypic testing is medically necessary before starting 6-mercaptopurine or azathioprine, with only one TPMT assay per member per lifetime, and NUDT15 gene analysis is medically necessary before starting any thiopurine (azathioprine, mercaptopurine or thioguanine). For IBD, fecal calprotectin is medically necessary for managing Crohn's disease and ulcerative colitis and for distinguishing IBD from irritable bowel syndrome, fecal lactoferrin is medically necessary for distinguishing IBD from irritable bowel syndrome, and 6-thioguanine nucleotide and 6-methylmercaptopurine nucleotide measurements are medically necessary to monitor compliance in patients not responding to 6-mercaptopurine and azathioprine therapy and to assess suspected toxicity. Many other biomarkers, antibody panels and genetic tests, including NOD2/CARD15 genotyping, PredictSURE IBD, Monitr Crohn's Disease Test and procalcitonin measurement, are considered experimental, investigational or unproven.
Aetna · Identified Aug 18, 2026Medium impact
Transanal Endoscopic Microsurgery (CPB 0747, reviewed 2025-11-26)
Aetna covers transanal endoscopic microsurgery (TEM) for benign rectal tumors (adenomas), low-risk Tis and T1 rectal carcinoma, and small rectal carcinoids less than 2 cm in diameter. Aetna considers TEM experimental, investigational, or unproven for other indications, including advanced rectal cancer, anorectal melanoma, benign rectal strictures, rectal prolapse and diverticula, rectal schwannoma, and recto-urinary and recto-vesical fistulas. The covered CPT code is 0184T, and the policy lists the ICD-10 codes that are covered if selection criteria are met and the codes not covered for the listed indications.
Aetna · Identified Aug 17, 2026Medium impact
Gastrointestinal Function: Selected Tests (CPB 0396, reviewed 2026-07-09)
Aetna considers colonic motility studies (colonic manometry) medically necessary to guide decision-making for surgery in children with refractory colonic motility or defecatory disorders. Aetna considers radionuclide gastric emptying studies medically necessary for the evaluation of gastrointestinal motility disorders and gastroparesis. Aetna considers magnetic resonance enterography medically necessary to evaluate and monitor Crohn's disease and other small bowel disorders. The following are considered experimental, investigational, or unproven because their effectiveness or clinical utility has not been established: 3D high-resolution manometry for quantification of esophago-gastric junction contractility; body surface gastric mapping (Gastric Alimetry) for gastric motility and gastroduodenal disorders and all other indications; electrogastrography; the gastric emptying breath test for gastroparesis and all other indications; high resolution esophageal pressure topography (HREPT); the immunoglobulin G antibody blood test to identify food triggers associated with irritable bowel syndrome (Biomerica inFoods IBS); the Malabsorption Evaluation Panel (Mayo Clinic Laboratories) for evaluation of intestinal dysbiosis, irritable bowel syndrome, malabsorption or small intestinal overgrowth of bacteria, and all other indications; the PillSense System for detection of upper gastrointestinal bleeding; and the SmartPill wireless capsule for measuring gastric emptying parameters for gastric disorders, intestinal motility disorders, and all other indications, because of inadequate published evidence of its diagnostic performance and clinical utility over conventional means of measuring gastric emptying. The policy lists CPT 91117 as covered for its listed indications and CPT 91132 and 91133 (electrogastrography) as not covered for those indications.
Aetna · Identified Aug 15, 2026Medium impact
Bowel Management Devices (CPB 0522, reviewed 2025-11-25)
Aetna considers manual pump enema systems (such as the Peristeen Anal Irrigation System) medically necessary for chronic neurogenic bowel when initial management involving diet, bowel habit, laxatives or constipating medications has failed, and considers gravity-administered enema systems medically necessary for constipation, fecal incontinence and bowel management protocols. Aetna also considers stents for bowel obstruction due to colorectal malignancy medically necessary for palliation and as a bridge to surgery. Aetna considers ingestible vibrating capsule devices (e.g., Vibrant System) for constipation, manual pump enema systems for idiopathic constipation and fecal incontinence, the Navina Smart System, pulsed irrigation evacuation systems for chronic constipation, and rectal inserts experimental, investigational or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Fecal Bacteriotherapy (CPB 0844, reviewed 2026-03-25)
Aetna's commercial clinical policy bulletin 0844 covers fecal bacteriotherapy. It considers fecal microbiota transplant medically necessary for Clostridium difficile infection (CDI) confirmed by a positive C. difficile toxin stool test that has recurred after at least one course of adequate antibiotic therapy. It considers a single rectal dose of Rebyota (fecal microbiota, live-jslm) medically necessary for preventing CDI when the policy's criteria are met, and it considers other listed indications, including alcoholic hepatitis, Crohn's disease, ulcerative colitis and irritable bowel syndrome, experimental, investigational, or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Celiac Disease Laboratory Testing (CPB 0561, reviewed 2026-08-03)
Serological testing for IgA anti-human tissue transglutaminase (TTG), IgG and IgA deamidated gliadin (DGP), and IgA anti-endomysial (EMA) antibodies is medically necessary as a preliminary diagnostic test for persons with symptoms suggestive of celiac disease, to monitor response to a gluten-free diet, to screen first-degree relatives of individuals with celiac disease, and to screen persons with type 1 diabetes. HLA-DQ2 and HLA-DQ8 genetic testing is medically necessary for listed situations, including seronegative persons with equivocal small bowel histology findings (Marsh I-II), evaluation of persons on a gluten-free diet in whom no serologic testing was performed before starting it, and persons with Down syndrome. Anti-gliadin antibody (AGA) and anti-reticulin antibody (ARA) testing, the Prometheus Celiac Plus Panel, and HLA genotyping for screening persons with type 1 diabetes are experimental, investigational, or unproven.
Aetna · Identified Aug 14, 2026Medium impact
Defecography (CPB 0718, reviewed 2025-10-14)
Defecography is medically necessary for members with documented chronic constipation when anorectal manometry and rectal balloon expulsion results are negative or inconclusive, and when anterior rectocele, enterocele, inappropriate contraction of the puborectalis muscle, or pelvic organ prolapse is suspected. MR defecography is medically necessary for evaluation or surgical planning of obstructed defecation syndrome and other functional defecation disorders when conventional tests, including conventional defecography, have been inconclusive. Defecography for routine evaluation of constipation and for pre-operative prediction of low anterior resection syndrome is considered experimental, investigational, or unproven, and MR defecography is considered experimental, investigational, or unproven for rectal prolapse, rectal intussusception, other pelvic floor disorders, and other indications.
Aetna · Identified Aug 12, 2026Medium impact
Biofeedback (CPB 0132, reviewed 2026-07-16)
Aetna considers biofeedback medically necessary for cancer pain, chronic constipation secondary to dyssynergic defecation as confirmed by anorectal manometry, fecal incontinence, irritable bowel syndrome, levator ani syndrome, migraine and tension headaches, refractory severe subjective tinnitus, temporomandibular joint syndrome, urinary incontinence, and neuromuscular rehabilitation of stroke and traumatic brain injury. Biofeedback is considered not medically necessary when used to improve emotional and physical health in non-diseased persons. EEG biofeedback is considered experimental, investigational, or unproven for migraine and tension headache, and several listed uses are experimental, including amygdala-related EEG neurofeedback for PTSD, HeartMath HRV biofeedback for headaches, InTandem for walking in chronic stroke, and surface EMG biofeedback for chronic ankle instability. Some Aetna plans exclude coverage of biofeedback.

Watch K59.09

Get one email when a payer policy names K59.09, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Transanal Endoscopic Microsurgery (CPB 0747, reviewed 2026-10-21)

Lead Testing (CPB 0553, reviewed 2026-08-28)

Bowel Management Devices (CPB 0522, reviewed 2026-08-18)

Inflammatory Disease: Biomarker and Thiopurine Pharmacogenomic Testing (CPB 0249, reviewed 2026-04-27)

Transanal Endoscopic Microsurgery (CPB 0747, reviewed 2025-11-26)

Gastrointestinal Function: Selected Tests (CPB 0396, reviewed 2026-07-09)

Bowel Management Devices (CPB 0522, reviewed 2025-11-25)

Fecal Bacteriotherapy (CPB 0844, reviewed 2026-03-25)

Celiac Disease Laboratory Testing (CPB 0561, reviewed 2026-08-03)

Defecography (CPB 0718, reviewed 2025-10-14)

Biofeedback (CPB 0132, reviewed 2026-07-16)

What insurance policy changes affect code K59.09?

Which payers have updated policy for code K59.09?

How do I get notified when code K59.09 policy changes?

Why do payers change policies for code K59.09?